Exchange: NASDAQ·Updated 07:59 PM EST

ABOS Earnings

Latest Earnings Results: Q3 '26

Reported: Oct 26

Estimated EPS

-$0.39

Reported EPS

-$0.35

Surprise

+9.93%

Estimated Rev

$0M

Reported Rev

---

Surprise

---

• Reported GAAP EPS of -$0.35 up 20.45% YoY • Acumen Pharmaceuticals expects its $78.6M in cash, cash equivalents and marketable securities as of September 30, 2026, to support current clinical and operational activities into early 2027.

Generated by Stocktwits using AI and company-reported earnings data for Q3 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.

10-Q

Historical Earnings

Quarterly

Annual

EPS

Revenue

Fiscal PeriodEstimatedReportedSurpriseResult
Q4 '26
-$0.40
--
--
N/A
Q3 '26
-$0.39
-$0.35
9.93%
BEAT
Q2 '26
-$0.36
-$0.45
-25.23%
MISSED
Q1 '26
-$0.40
-$0.33
18.07%
BEAT
Q4 '25
-$0.46
-$0.40
12.98%
BEAT

Advertisement|Remove ads.